Products for Research Use Only
RegisterLogin

Chlorzoxazone

CAT: 0804-HY-B1462-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1462-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis[1][2][3][4][5][6][7][8][9][10].
CAS Number
95-25-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Amyloid-β; Cytochrome P450; FOXO; Potassium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Chlorzoxazone.html
Purity
99.91
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C1OC2=CC=C(Cl)C=C2N1
Molecular Formula
C7H4ClNO2
Molecular Weight
169.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Yamamura Y, et al. Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica. 2015 Apr;45 (4) :353-360.|[2]Lu T, et al. Action of chlorzoxazone on Ca2+movement and viability in human oral cancer cells. Chin J Physiol. 2019 May-Jun;62 (3) :123-130.|[3]Deng L, et al. Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation. Cell Death Dis. 2020 Mar 2;11 (3) :158. |[4]Lv J, et al. Chlorzoxazone Alleviates Experimental Autoimmune Encephalomyelitis via Inhibiting IL-6 Secretion of Dendritic Cells. J Immunol. 2022 Apr 1;208 (7) :1545-1553.|[5]Liu YC, et al. Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. Brain Res. 2003 Jan 3;959 (1) :86-97.|[6]Bai Y, et al. Chlorzoxazone exhibits neuroprotection against Alzheimer's disease by attenuating neuroinflammation and neurodegeneration in vitro and in vivo. Int Immunopharmacol. 2020 Nov;88:106790.|[7]Dong DL, et al. Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545 (2-3) :161-6.|[8]Gao L, et al. Chlorzoxazone or 1-EBIO increases Na (+) absorption across cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281 (5) :L1123-9.|[9]Baek HW, et al. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci. 2006 Nov;95 (11) :2452-62. |[10]Hopf FW, et al. Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry. 2011 Apr 1;69 (7) :618-24.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CYP2

Alternative Products

CatalogName
FC20416Chlorzoxazone

Popular Products